this study determined the clinical effect of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. the study was an off-label, single-dosing, interventional case series involving 22 patients with primary and recurrent pterygium. they received subconjunctival bevacizumab (0.2cc). pterygium vascularity and thickness was graded. the size of the pterygium (...
